Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group protocol 076

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 557-564

  Eastman, P Scott ^b   Shapiro, David E ^b   Coombs, Robert W ^a   Frenkel, Lisa M ^b   McSherry, George D ^b   Britto, Paula ^b   Herman, Steven A ^b   Sperling, Rhoda S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MATERNAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VERTICAL TRANSMISSION; VIRUS TYPING;

EID: 0031912007     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514228     Document Type: Article

References (24)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
3. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243: 1731-4.
4. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-44.
5. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment. J Infect Dis 1992; 165:105-10.
6. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995;171:1172-9.
7. De Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996;93:5501-6.
8. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174: 704-12.
9. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in HIV reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167: 526-32.
10. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
11. Sonnerburg A, Johansson B, Ayehunie S, Julander I. Transmission of zidovudine-resistant HIV-1 [letter]. AIDS 1993;7:1684-5.
12. Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type-1 zidovudine resistance. J Clin Microbiol 1995;33:2777-80.
13. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 1995;33:342-7.
14. Cochran WG. Sampling techniques. New York: Wiley, 1977.
15. Kupper LL, McMichael AJ, Spirtas R. A hybrid epidemiologic study design useful in estimating relative risk. J Am Stat Assoc 1995;70: 524-8.
16. Louis TA. Confidence intervals for a binomial parameter after observing no successes. Am Stat 1981;35:154.
17. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
18. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-9.
19. Barzilai A, Sperling RS, Hyatt AC, Wedgwood JF, Reidenberg BE, Hodes DS. Mother to child transmission of human immunodeficiency virus 1 infection despite zidovudine therapy from 18 weeks of gestation. Pediatr Infect Dis J 1990;9:931-3.
20. Frenkel LM, Wagner LEN, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995;20:1321-6.
21. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1 - infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:232-6.
22. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43(RR-11):1-20.
23. Mayers DL, Yerly S, Perrin L, et al. Prevalence and clinical course of persons seroconverting with AZT-resistant (AZTR) HIV-1 in Switzerland, Australia, and the United States between 1988 and 1994 [abstract 392], AIDS Res Human Retroviruses 1995;11:S162.
24. Weiser B, Burger H, Weislow O, et al. AZT resistance and HIV-1 mother-to-child transmission. In: 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996.